International Journal of Pharmaceutical Science Invention
ISSN (Online): 2319-6718, ISSN (Print): 2319- 670X
www.ijpsi.org Volume 14 Issue 3 ǁ May –June, 2025 ǁ PP. 135-139

Pulsatile Drug Delivery Systems for the Treatment of Asthma

Azad Singh[1*], Praveen Tahilani[1]
[1]*Faculty of Pharmacy, Sanjeev Agrawal Global Education (SAGE) University, Bhopal, Madhya Pradesh, India*
**Corresponding Author: Azad Singh*
Email: azadsingh25112001@gmail.com

Abstract
Asthma, a chronic respiratory disease, often exhibits nocturnal exacerbations, presenting a challenge for conventional therapies. Pulsatile drug delivery systems, designed to release medication at specific times, offer a chronotherapeutic approach to address this issue. This review explores the application of pulsatile drug delivery in asthma management, focusing on its potential to target nighttime symptoms. We discuss the circadian rhythm of asthma, the principles of pulsatile drug delivery, and various technological approaches employed, including capsular, osmotic, and coated tablet systems. Preclinical studies demonstrating the feasibility of achieving controlled lag times and drug release profiles are highlighted, along with the anti-asthmatic drugs commonly investigated. The review also addresses the challenges associated with the development and clinical translation of these systems and outlines potential future research directions, such as the use of novel materials, targeted delivery, personalized medicine, and integration with smart technologies. Ultimately, pulsatile drug delivery systems hold significant promise for improving asthma treatment, particularly nocturnal asthma, by optimizing drug delivery timing to enhance efficacy and patient compliance while minimizing side effects.
Keywords: *Asthma, Pusatile delivery, chronotherapy, controlled release,*

Date of Submission: 05-06-2025 Date of acceptance: 17-06-2025

I. Introduction

Asthma, a prevalent chronic respiratory ailment, is characterized by inflammation and narrowing of the airways, affecting a substantial portion of the global population.[1] While current therapeutic strategies involving inhaled corticosteroids, long-acting beta-agonists, and short-acting beta-agonists are often effective, a subset of patients experiences persistent, inadequately controlled symptoms, underscoring the necessity for innovative therapeutic interventions.[1] Pulsatile drug delivery systems represent a sophisticated approach engineered to release medications at specific time points, aligning with the body's inherent circadian rhythms.[3] This concept, known as chronotherapy, holds particular significance for diseases exhibiting time-dependent symptom patterns.[4] This review article will delve into the application of pulsatile drug delivery systems for the management of asthma, with a particular emphasis on addressing the challenges associated with nocturnal asthma and the potential advantages of precisely timed drug release.

Asthma symptoms frequently manifest a distinct circadian rhythm, with a notable exacerbation observed during the night and the early morning hours, a phenomenon widely recognized as nocturnal asthma.[11] Research indicates that a considerable percentage of individuals with asthma experience symptoms severe enough to disrupt sleep.[13] This nocturnal worsening is not merely a consequence of sleep itself but is intrinsically linked to the body's internal clock.[18] Various physiological factors contribute to this phenomenon, including cyclical variations in hormone levels such as cortisol and epinephrine, increased responsiveness of the airways, diminished lung function, heightened activity of the vagal nerve, and elevated levels of inflammatory mediators.[13] The intricate interplay of these factors suggests a complex underlying mechanism driving nocturnal asthma, highlighting the need for therapeutic strategies that can address these dynamic physiological changes.[13] A clear understanding of these temporal patterns is paramount in designing effective drug delivery systems capable of providing optimal drug concentrations precisely when they are most needed, particularly during the early morning hours, which are often associated with a higher incidence of asthma attacks.[8]

Pulsatile Drug Delivery

Pulsatile drug delivery systems are distinguished by their ability to release a specific quantity of drug molecules rapidly and transiently within a short timeframe, immediately following a predetermined period of minimal or no drug release, known as the lag time.[4] This unique release profile is designed to mimic the body's inherent biological rhythms and the temporal patterns of disease progression.[4] The defining characteristic of

PDDS, the lag time followed by a burst release, directly addresses the need for timed drug administration in chronotherapeutic applications such as asthma.[4] Compared to conventional immediate-release and sustained-release formulations, PDDS offer several potential advantages in the context of asthma treatment.[4] By ensuring that the drug is available at the time when symptoms are most severe, such as during the early morning for individuals with nocturnal asthma, PDDS can potentially lead to enhanced therapeutic outcomes.[4] This synchronization of drug release with the circadian rhythm of asthma could result in more effective control of symptoms compared to maintaining constant drug levels throughout the day and night.[4] Furthermore, PDDS can be designed for convenient once-daily administration, typically taken at bedtime to release the medication during the critical nighttime hours, which can significantly improve patient adherence to the prescribed treatment regimen.[3] The potential for reduced dosing frequency simplifies the treatment schedule, a crucial factor in promoting compliance for chronic conditions like asthma.[3] The convenience of fewer doses and the prospect of better symptom management can collectively contribute to increased adherence to the medication regimen.[4] Moreover, by delivering the drug specifically when it is most needed, the overall exposure to the medication might be reduced, potentially leading to a decrease in the occurrence of side effects.[3] This targeted drug release inherent in PDDS could minimize systemic exposure, thereby reducing the likelihood of adverse effects.[3] The fundamental design of PDDS aims to synchronize drug delivery with the body's natural circadian rhythms, thereby optimizing the therapeutic effect.[3] Additionally, the pulsatile nature of drug release can potentially help prevent the downregulation of drug receptors that can occur with continuous exposure to medication.[7]

Chronotherapy of Asthma

A multitude of technological approaches have been explored for the development of pulsatile drug delivery systems tailored for asthma treatment.[5] Capsular systems often involve a drug-containing core enclosed within an insoluble capsule body, sealed with a plug, frequently composed of a hydrogel material, that swells or erodes over a defined period, resulting in drug release after a specific lag time.[5] The Pulsincap system stands out as a prominent example of this technology.[11] For instance, one study detailed the formulation of a modified Pulsincap system designed for the delivery of albuterol sulfate and theophylline, utilizing a hydrogel plug to achieve the desired lag time necessary for the chronotherapy of asthma.[49] Another investigation focused on the development and evaluation of a theophylline pulsatile system that employed an impermeable capsule body and an erodible tablet plug to achieve a 5-hour delay in drug release, specifically targeting nocturnal asthma.[24] These examples illustrate the versatility of capsular systems in achieving time-controlled release through careful manipulation of the plug and capsule properties.[24] Osmotic systems represent another significant approach, harnessing osmotic pressure to precisely control the release of medication. In these systems, water permeates through a semi-permeable membrane into the device, dissolving or suspending the drug, which is subsequently expelled through a small orifice after a predetermined lag time.[5] The Port system is a notable example of an osmotic drug delivery system.[38] One study described the design and evaluation of an osmotically controlled pulsatile release capsule containing montelukast sodium, intended for the prevention of asthma attacks occurring in the early morning hours. This system successfully achieved a lag time of 4.5 hours, followed by a rapid release of the drug.[31] Osmotic systems offer a reliable mechanism for achieving pulsatile release, demonstrating a degree of independence from the pH environment within the gastrointestinal tract.[31] Coated tablets constitute another widely explored technology, where core tablets containing the anti-asthmatic drug are coated with polymers that are sensitive to either pH or time. Drug release is triggered once the coating dissolves or erodes after a specific lag period or upon encountering a particular pH condition within the gastrointestinal tract.[5] Press-coated tablets are also frequently utilized in this context.[25] For example, research has been conducted on the development of a pulsatile orciprenaline sulfate drug delivery system utilizing pH-sensitive polymers such as Eudragit S-100 and Eudragit L100 to delay the release of the drug, specifically for the treatment of nocturnal asthma.[26] Another study detailed the formulation of press-coated salbutamol sulfate tablets designed to exhibit a 6-hour lag time, employing a combination of ethylcellulose and hydroxypropyl cellulose as coating materials.[25] Coating technology provides a high degree of control over both the lag time and the subsequent drug release profile through the careful selection of appropriate polymers and the precise adjustment of coating thicknesses.[25] Multiparticulate systems involve the formulation of the drug into numerous small units, such as pellets, which are then coated to provide the desired pulsatile release characteristics. This approach can offer advantages in terms of more predictable gastric emptying and a reduced risk of a phenomenon known as dose dumping, where the entire drug content is released prematurely.[12] One study described the development of theophylline fast-release enteric-coated pellets as a pulsatile drug delivery system specifically targeted for colonic delivery, which is relevant in the context of chronopharmaceutical drug administration.[12] Multiparticulate systems can enhance the reliability and predictability of pulsatile drug delivery compared to single-unit dosage forms.[12] While less commonly explored for asthma in the provided research, externally triggered systems represent an innovative area where drug release can be initiated by external stimuli such as ultrasound [34], magnetic fields [36], or light.[36] One study presented a proof of concept for a pulsatile drug delivery system that could be remotely activated by the acoustic radiation force of

ultrasound.[34] Externally triggered systems hold the potential for on-demand drug release, offering maximum control over the timing of medication administration.[34]

The mechanisms that govern drug release from pulsatile drug delivery systems designed for asthma are varied and are contingent upon the specific technology employed.[5] pH-dependent release involves the utilization of coatings made from polymers like Eudragit S-100, which dissolve at specific pH levels encountered in the gastrointestinal tract, typically at the higher pH values present in the intestine or colon. This dissolution process triggers the release of the drug after the dosage form has traversed the acidic environment of the stomach.[12] For instance, pH-sensitive polymers have been employed to ensure minimal drug release in the stomach and upper intestine, with the intended release occurring later in the gastrointestinal tract, which is particularly relevant for the treatment of nocturnal asthma.[26] Another study described a pH-sensitive system that utilized a combination of polyacrylic acid and ethyl cellulose to achieve an on-off pulsed release of a bronchodilator medication.[28] pH-dependent systems can effectively provide a time delay in drug release that is based on the transit time of the dosage form through the different pH environments of the gastrointestinal tract.[26] Time-controlled release, in contrast, relies on the predictable erosion or swelling of polymeric materials over time. This process leads to drug release after a predetermined lag period that is independent of the surrounding pH.[4] Hydrogel plugs used in capsular systems also exhibit swelling behavior that is dependent on time.[24] As an example, a study employed a barrier layer composed of ethylcellulose and hydroxypropyl cellulose that eroded over a period of 6 hours to achieve a controlled lag time for the release of salbutamol sulfate.[25] Another investigation utilized an erodible tablet plug made from HPMC to precisely control the lag time in a theophylline pulsatile capsule.[24] Time-controlled systems offer a more direct approach to achieving a specific delay before drug release, which is particularly crucial for aligning with predictable circadian events such as nocturnal asthma symptoms.[24] Osmotic pressure-driven release operates through the influx of water across a semi-permeable membrane into the drug delivery system. This water influx generates pressure within the system, which then forces the drug out through a specifically designed delivery orifice after a lag time that is determined by the system's overall design.[5] Swelling and rupture is another mechanism utilized in some pulsatile systems. These systems incorporate a swelling layer that expands gradually over time, eventually causing an outer membrane to rupture and release the drug payload.[35] Finally, stimuli-responsive release mechanisms are employed in certain advanced systems, where the drug is released in response to specific external or internal triggers, such as changes in temperature or the presence of particular molecules.[7] While less commonly reported for asthma in the provided research, this area holds significant potential for future development of highly targeted and responsive drug delivery systems.

The provided research highlights several preclinical investigations focused on the development and evaluation of pulsatile drug delivery systems for the treatment of asthma.[24] These studies predominantly involve in vitro dissolution testing, a crucial method for characterizing the drug release profiles and the lag times achieved by various formulations.[24] For instance, one study evaluated a modified pulsincap system designed to deliver albuterol sulfate and theophylline, successfully demonstrating a controlled release of the drugs after a predetermined lag period under in vitro conditions.[49] Another investigation showed that a press-coated tablet formulation of salbutamol sulfate was able to achieve a lag time of approximately 6 hours, followed by a rapid release of the drug in vitro.[25] Furthermore, one study provided in vivo pharmacokinetic data obtained from rabbits for an osmotically controlled pulsatile release capsule containing montelukast sodium. The results of this study indicated a delayed Tmax, which was consistent with the intended lag time designed into the system.[31] These preclinical in vitro studies are of paramount importance in optimizing the lag time and the overall release characteristics of pulsatile drug delivery systems to ensure they align with the desired therapeutic window for asthma management.[25] Several of these studies specifically aimed to achieve a lag time in the range of 4 to 6 hours, a duration intended to target the early morning exacerbations of asthma symptoms that are frequently observed in patients.[23] The anti-asthmatic drugs that were commonly investigated in these preclinical studies include theophylline [12], salbutamol sulfate [25], orciprenaline sulfate [26], and montelukast sodium.[27] The focus on these specific bronchodilators and leukotriene receptor antagonists in the research on pulsatile drug delivery systems underscores their critical role in managing asthma, particularly the symptoms that occur during the night.[25] While in vivo studies were less prevalent in the provided research, the one study that did provide pharmacokinetic data in rabbits [31] highlights the essential role of such investigations in confirming the performance of pulsatile drug delivery systems within a biological system and in establishing a correlation between the findings obtained from in vitro experiments and the actual drug absorption and release patterns observed in living organisms.[31]

Despite the considerable promise that pulsatile drug delivery systems hold for the treatment of asthma, several challenges must be effectively addressed to facilitate their widespread clinical application.[5] Ensuring the reproducibility and reliability of achieving consistent lag times and drug release profiles across different production batches and under varying in vivo conditions can be a significant hurdle.[5] The manufacturing processes involved in creating sophisticated pulsatile drug delivery systems can be complex, often requiring multiple steps and potentially leading to higher production costs compared to conventional pharmaceutical formulations.[5] The

performance of these systems can also be influenced by inherent in vivo variability, including factors such as gastric emptying time, the motility of the intestines, and differences in physiological parameters among individual patients.[5] Furthermore, some pulsatile drug delivery technologies may have limitations regarding the maximum amount of drug that can be incorporated into the system.[5] Maintaining the stability of both the drug and the delivery system throughout the product's shelf life is also a critical consideration to ensure its safety and efficacy. Future research endeavors in this field could focus on several key areas. The development of novel materials, including polymers, with specifically tailored properties could lead to more precise and reliable control over pulsatile drug release.[56] Combining pulsatile drug delivery systems with targeted delivery strategies, such as using nanoparticle-based systems, to direct the medication specifically to the lungs or even to particular cells within the lungs, holds the potential to enhance therapeutic efficacy while simultaneously reducing systemic side effects.[2] Nanotechnology is showing considerable promise in this area.[2] Adopting personalized medicine approaches, where the lag time and release profile of pulsatile drug delivery systems are tailored to an individual patient's unique circadian rhythms and the specific severity of their asthma, could further optimize treatment outcomes.[3] The integration of pulsatile drug delivery systems with smart technologies, such as wearable sensors or mobile applications, could enable real-time monitoring and adjustment of drug delivery, leading to more dynamic and effective asthma management.[60] Finally, conducting more extensive clinical trials in human patients is crucial for thoroughly evaluating the safety and efficacy of pulsatile drug delivery systems for asthma in real-world settings.[26] The current body of research, as reflected in the provided snippets, primarily focuses on preclinical investigations, highlighting the need for further clinical validation.

In conclusion, pulsatile drug delivery systems present a promising avenue for transforming the treatment of asthma, particularly by addressing the challenges associated with nighttime symptoms through the administration of medication aligned with the body's natural rhythms. By carefully engineering these systems to release anti-asthmatic drugs at the most opportune times, it may be possible to achieve improved therapeutic efficacy, enhance patient adherence to treatment, and minimize the occurrence of undesirable side effects. Continued research and development efforts in this field, with a focus on exploring innovative technologies, implementing targeted delivery strategies, and conducting comprehensive clinical evaluations, are essential for fully realizing the potential of pulsatile drug delivery systems in the effective management of asthma.

References

[1]. Zhen G, Yingying L, Weifang X, Jingcheng D. Abibliometric and scientific knowledge map study of the drug therapies for asthma-related study from 1982 to 2021. Frontiers in Pharmacology. 2022; 13. https://doi.org/10.3389/fphar.2022.916871

[2]. Borghi SM, Zaninelli TH, Carra JB, Heintz OK, Baracat MM, Gerogetti SR, Vincentini FTMC, Verri WA, Casagrande R. Therapeutic Potential of Controlled Delivery Systems in Asthma: Preclinical Development of Flavonoid-Based Treatments. Pharmaceuticals. 2023; 15(1): 1. https://doi.org/10.3390/pharmaceutics15010001

[3]. Manjunath G, Nirmala S. Chronomodulated drug delivery: Challenges, benefits, and future direction in asthma. Intelligent Pharmacy. 2024; 2(1): 150-154

[4]. Gangadhar B, Sai Bhanu Sree B, Swamy PV, Aruna Devi M. Pulsatile drug delivery system: A review – International Journal of Research in Ayurveda and Pharmacy. 2022; 13(6): 124-130

[5]. Anusha V, Umashankar MS, Ganesh Kumar Y. Pulsatile drug delivery system — an innovative method to treat chronotherapeutic diseases by synchronizing drug delivery with circadian rhythm. Journal of Applied Pharmaceutical Science. 2023; 13(12). DOI: 10.7324/JAPS.2023.125025

[6]. Jain D, Raturi R, Jain V, Bansal P, Singh R. Recent technologies in pulsatile drug delivery systems. Biomatter. 2011; 1(1): 57-65

[7]. Pal S, Monika, Singh M. Circadian rhythms regulated pulsatile drug delivery system. International Journal of Health Sciences. International Journal of Health Sciences. 2022; 6(S4): 7944-7965.

[8]. Singh A, Dubey H, Shukla I, Singh DP. Pulsatile Drug Delivery System: an Approach of Medication according to Circadian Rhythm. Journal of Applied Pharmaceutical Science. 2012; 2(3). DOI: 10.7324/JAPS.2012.2327

[9]. Rajput A, Pingale P, Telange D, Musale S, Chalikwar S. A current era in pulsatile drug delivery system: Drug journey based on chronobiology. Heliyon. 2024; 10(10): e29064.

[10]. Khan S, Monika. Circadian rhythms regulated asthma treatment by virtue of pulsatile drug delivery system. International Journal of Applied Pharmaceutics. 2022; 14(4). https://doi.org/10.22159/ijap.2022v14i4.44395

[11]. Padhye SU, Rahate AC, Pomaje MD. Formulation and evaluation of pulsatile drug Delivery System for Nocturnal Asthma using Ficus religiosa. The Bioscan. 2025; 20(S2): 113-120

[12]. Kadam VD, Gattani SG. Development of colon targeted multiparticulate pulsatile drug delivery system for treating nocturnal asthma. Drug Delivery. 2010; 17(5): 343-351

[13]. Martin RJ. Nocturnal Asthma: Circadian Rhythms and Therapeutic Interventions. American Review of Respiratory Disease. 2000; 147 (6pt2). https://doi.org/10.1164/ajrccm/147.6_Pt_2.S25

[14]. Xiongbing J. Nocturnal Asthma: A special type of asthma. Global Journal of Allergy. 2016; 2(1): 003-009

[15]. Syabbalo N. Chronobiology and chronopathophysiology of nocturnal asthma. Int J Clin Pract. 1997; 51(7): 455-462.

[16]. Smolensky MH, Barnes PJ, Reinberg A, McGovern JP. Chronobiology and asthma. I. Day-night differences in bronchial patency and dyspnea and circadian rhythm dependencies. 1986; 23(6): 321-343

[17]. Sellman TK. 2023. The Link Between Asthma and Circadian Rhythms, accessed on May 16, 2025, https://asthma.net/living/research-circadian-rhythms

[18]. Bridger H. Circadian Rhythm and Asthma. accessed on May 16, 2025, https://hms.harvard.edu/news/circadian-rhythm-asthma

[19]. Martin RJ. Chronobiology of Asthma. American Journal of Respiratory and Critical Care Medicine. 1997; 158(3): 1002-1007

[20]. Scheer FAJL, Hilton FH, Evoniuk HL, Shea SA. The endogenous circadian system worsens asthma at night independent of sleep and other daily behavioral or environmental cycles Proceedings of the National Academy of Science. 2021; 118(37): e2018486118

[21]. Burioka N, Suyama H, Sako T, Shimizu E. Circadian rhythm in peak expiratory flow: alteration with nocturnal asthma and

theophylline chronotherapy. Chronobiology International. 2000; 17(4): 513-519
[22]. Sirisha VNL, Namrata M, Sruthi B, Harika I, Kiran Kumar Rao Y, Pranavi K. Pulsatile Drug Delivery System-A Review. International Journal of Pharmaceutical Research and Allied Sciences. 2012; 1(3): 13-23
[23]. Khan S, Monika. Circadian rhythms regulated asthma treatment by virtue of pulsatile drug delivery system. International Journal of Applied Pharmaceutics. 2022; 14(4): 1-8
[24]. Mahajan A, Pancholi SS. Pulsatile Drug Delivery for the Treatment of Nocturnal Asthma: a Chronopharmaceutical Approach. Latin American Journal of Pharmacy. 2010; 29(1): 153-156
[25]. Adhikari C, Kulkarni GS, Swamy S. Formulation and evaluation of pulsatile drug delivery system of salbutamol sulfate for the chronotherapy of asthma. Asian Journal of Pharmaceutical and Clinical Research. 2018; 11(9): 305-311.
[26]. Gowri S, Chintapalli, Behera SR, Jena D, Tripathy P, Dash A, Mishra K. Design Development and Evaluation of Pulsatile Drug Delivery System of Orciprenaline Sulfate for the Treatment of Nocturnal Asthma. Indian Journal of Natural Sciences. 2023; 14(77): 54108-54117
[27]. Shrishailappa DD, Tikare N, Halakatti P, Desai A, Muchandi I. Formulation and Evaluation of Pulsatile Drug Delivery System of Montelukast Sodium. RGUHS Journal of Pharmaceutical Sciences. 2018; 8(2): 45-59
[28]. Tran PHL, Choe JS, Tran TTD, Park YM, Lee BL. Design and Mechanism of On–Off Pulsed Drug Release Using Nonenteric Polymeric Systems via pH Modulation. AAPS PharmSciTech. 2010; 12(1): 46-55
[29]. Bodke V, Tekade BW, Badekar R, Phalak SD, Kale M. Pulsatile drug delivery systems the novel approach. International Journal of Pharmacy and Pharmaceutical Sciences. 2023; 16(2): 1-11
[30]. Shiva Krishna N, Jayanthi B, Madhukar A. Formulation development and evaluation of chronomodulated drug delivery system by zafirlukast. International Journal of Applied Pharmaceutics. International Journal of Applied Pharmaceutics. 2021; 13(4).
[31]. Ranjan OP, Nayak UY, Sreenivasa Reddy M, Dengale SJ, Musmade PB, Udupa N. Osmotically controlled pulsatile release capsule of montelukast sodium for chronotherapy: Statistical optimization, in vitro and in vivo evaluation. Drug Delivery. 2014; 21(7): 509-518
[32]. Sadaphal KP, Thakare V, Gandhi BR, Tekade BW. Formulation and evaluation of pulsatile drug delivery system for chronobiological disorder: Asthma. International Journal of Drug Delivery. 2011; 3(2). Doi: 10.5138/ijdd.v3i2.231
[33]. Tekade AR, Gattani SG. Development and evaluation of pulsatile drug delivery system using novel polymer. Pharmaceutical Development Technology. 2009; 14(4): 380-387
[34]. Ciancia S, Cafarelli A, Zahoranova A, Menciassi A, Ricotti L. Pulsatile Drug Delivery System Triggered by Acoustic Radiation Force. Frontiers in Bioengineering and Biotechnology. 2020; 8. https://doi.org/10.3389/fbioe.2020.00317
[35]. Venkataswamy R, Nallaguntal L. Pulsatile drug delivery system. Asian Journal of Pharmaceutical and Clinical Research. 2021; 14(6): 48-59
[36]. Lalwani A, Santani DD. Pulsatile drug delivery systems. Indian Journal of Pharmaceutical Sciences. 2007; 69(4): 489-497
[37]. Juturi RKR, Veera JM, Sheikuduman MST, Chetty CMS. Review on: Pulsatile Drug Delivery Systems. Journal of Pharmaceutical Sciences and Research. 2009; 1(4): 109-115
[38]. Arora S, Ali J, Ahuja A, Baboota S, Qureshi J. Pulsatile Drug Delivery Systems: An Approach for Controlled Drug Delivery. Indian Journal of Pharmaceutical Sciences. 2006; 68(3): 295-300
[39]. Rajput A, Pingale P, Telange D, Musale S, Chalikwar S. A current era in pulsatile drug delivery system: Drug journey based on chronobiology. Heliyon. 2024; 10(10): e29064.
[40]. Mahajan KR, Gorle AP, Khalane VS. Overview on pulsatile drug delivery system - International Journal of Science and Research Archive. 2022; 5(2): 110-118
[41]. Hussein M, Nathir I. Pulsatile Drug Delivery System Utilizing Innovative Technology. Pakistan Journal of Medical & Health Sciences. 2022; 16(6): 601.
[42]. Rajput A, Pingale P, Telange D, Musale S, Chalikwar S. A current era in pulsatile drug delivery system: Drug journey based on chronobiology. Heliyon. 2024; 10(10): e29064.
[43]. Khublal, Morris SS, Arya A. Formulation and Evaluation of Pulsatile Drug Delivery System of Anti-Asthmatic Drug. International Journal of Pharmacy & Pharmaceutical Research. 2023; 27(4): 238-270
[44]. Gangadhar B, Sai Bhanu Sree B, Swamy PV, Aruna Devi M. Pulsatile drug delivery system – A Review. International Journal of Research in Ayurveda and Pharmacy. 2022; 13(6): 124-130
[45]. Ravichandran V, Suba V, Senthilnathan B, Rajachandrika K, Padmapriya S, Saraswathy T. Pulsatile Drug Delivery System. Biomedical and Pharmacology Journal. 2009; 2(2): 749
[46]. Singh A, Dubey H, Shukla I, Singh DP. Pulsatile Drug Delivery System: an Approach of Medication according to Circadian Rhythm. Journal of Applied Pharmaceutical Science. 2012; 2(3): 166-176
[47]. Govinda Reddy G, Jat RK, Manjanna KM. Design, Evaluation and Optimization of Albuterol Sulphate and Theophylline Pulsincap drug delivery system for chronotherapy of Asthma. Journal of Drug Delivery and Therapeutics. 2024; 14(2): 134-141
[48]. Gao J, Karp JM, Langer R, Joshi N. The Future of Drug Delivery. Chemistry of Materials. 2023; 35(2): 359-363
[49]. Govinda Reddy G, Jat RK, Manjanna KM. Formulation and Evaluation of Pulsatile drug delivery of Albuterol sulphate and Theophylline drugs using modified Pulsincap technology. 2024; 14(2): 127-133
[50]. Bodke V, Tekade B, Mali A, Waghmare K. Formulation and Evaluation of Pulsatile Drug Delivery System by Press Coating Method for Treatment of COPD (Asthma). 2024; 14(4): 2249-2257